Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
|Articles|November 6, 2014
- November 2014
- Volume 1
- Issue 3
Age-related Diseases Don't Occur Earlier in HIV-infected Patients
Author(s)Jacquelyn Gray
Despite previous research suggesting HIV patients have an increased likelihood of suffering from a heart attack, kidney failure, or cancer, Johns Hopkins Bloomberg School of Public Health investigators showed the age they encounter these conditions were similar to their uninfected counterparts.
Advertisement
Despite previous research suggesting HIV patients have an increased likelihood of suffering from a heart attack, kidney failure, or cancer, Johns Hopkins Bloomberg School of Public Health investigators showed the age they encounter these conditions were similar to their uninfected counterparts.
For their study published in Clinical Infectious Diseases, researchers looked at the data of 98,687 veterans — 31% being HIV positive. To determine if HIV influenced age in which several diseases occur, they looked for myocardial infarction (MI), end-stage renal disease (ESRD), and non-AIDS-defining cancers (NADC) outcomes, and compared the ages when the incidents occurred to uninfected subjects.
From the 689 MI, 1,135 ESRD, and 4,179 NADC diagnoses occurring during the study period, the researchers noted the “mean age at MI (adjusted mean difference: -0.11 (95% confidence interval [-0.59, 0.37] years) and NADC (adjusted mean difference: -0.10 [-0.30, 0.10] years), did not differ by HIV status”. However, HIV-infected adults were diagnosed with ESRD were “at an average age of 5.5 months younger than uninfected adults (adjusted mean difference: -0.46 [-0.86, -0.07] years)”.
The authors supported previous research in that they found HIV-patients had a higher occurrence rate of all three conditions than uninfected persons.
"We did not find conclusive evidence to suggest that screening for these diseases should occur at younger ages in HIV-infected compared with uninfected adults,” said Keri N. Althoff, PhD, MPH, an assistant professor in the Department of Epidemiology at the Bloomberg School and the study’s lead author.
While their findings indicate the successes of antiretroviral therapy (ART) — one being their increase in life expectancy — HIV-infected patients have long claimed their quality of life is still subpar, causing them to feel they are aging faster.
Althoff echoed their sentiments, and cautioned their findings didn’t indicate that HIV patients are just as healthy as uninfected individuals.
"Many HIV-infected adults feel older than their age," she said. "Our study looks at three important age-related diseases and we find no meaningful difference in age at diagnosis. But this isn't the whole story. We need more research to figure out what is going on."
Articles in this issue
almost 12 years ago
New Study Provides Hope for Chronic Lyme Disease Sufferersalmost 12 years ago
New Line of HIV Treatment Identified for Patients Ineligible for Efavirenzalmost 12 years ago
Diarrhea Superbug Infections Doublealmost 12 years ago
Tenofovir Plus Interferon Improves Antigen Clearance in Chronic Hepatitis Balmost 12 years ago
Researchers Grow Human Norovirus Culturealmost 12 years ago
DNA Sequencing Could Lead to More Accurate Pneumonia DiagnosisAdvertisement
Related to this article
In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
Widespread antimicrobial use disrupts vital microbial communities that regulate Earth’s biogeochemical cycles, driving antimicrobial resistance, worsening human and environmental health, and significantly contributing to climate change.
New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Advertisement
Advertisement